1. ZHAW digitalcollection
  2. Angewandte Psychologie
  3. Publikationen
  4. Publikationen Angewandte Psychologie
Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-18108
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPlöderl, Martin-
dc.contributor.authorHengartner, Michael Pascal-
dc.date.accessioned2019-09-05T13:37:09Z-
dc.date.available2019-09-05T13:37:09Z-
dc.date.issued2019-
dc.identifier.issn1471-244Xde_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/18108-
dc.description.abstractSeveral international guidelines for the acute treatment of moderate to severe unipolar depression recommend a first-line treatment with antidepressants (AD). This is based on the assumption that AD obviously outperform placebo, at least in the case of severe depression. The efficacy of AD for severe depression can only be definitely clarified with individual patient data, but corresponding studies have only been available recently. In this paper, we point out discrepancies between the content of guidelines and the scientific evidence by taking a closer look at the German S3-guidelines for the treatment of depression. Based on recent studies and a systematic review of studies using individual patient data, it turns out that AD are marginally superior to placebo in both moderate and severe depression. The clinical significance of this small drug-placebo-difference is questionable, even in the most severe forms of depression. In addition, the modest efficacy is likely an overestimation of the true efficacy due to systematic method biases. There is no related discussion in the S3-guidelines, despite substantial empirical evidence confirming these biases. In light of recent data and with their underlying biases, the recommendations in the S3-guidelines are in contradiction with the current evidence. The risk-benefit ratio of AD for severe depression may be similar to the one estimated for mild depression and thus could be unfavorable. Downgrading of the related grade of recommendation would be a logical consequence.de_CH
dc.language.isoende_CH
dc.publisherBioMed Centralde_CH
dc.relation.ispartofBMC Psychiatryde_CH
dc.rightshttp://creativecommons.org/licenses/by/4.0/de_CH
dc.subject.ddc616.8: Neurologie und Krankheiten des Nervensystemsde_CH
dc.titleGuidelines for the pharmacological acute treatment of major depression : conflicts with current evidence as demonstrated with the German S3-guidelinesde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementAngewandte Psychologiede_CH
zhaw.organisationalunitPsychologisches Institut (PI)de_CH
dc.identifier.doi10.1186/s12888-019-2230-4de_CH
dc.identifier.doi10.21256/zhaw-18108-
zhaw.funding.euNode_CH
zhaw.issue265de_CH
zhaw.originated.zhawYesde_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume19de_CH
zhaw.publication.reviewOpen peer reviewde_CH
zhaw.webfeedKlinische Psychologiede_CH
zhaw.author.additionalNode_CH
Appears in collections:Publikationen Angewandte Psychologie

Files in This Item:
File Description SizeFormat 
DGPPN depression guideline.pdfPaper638.91 kBAdobe PDFThumbnail
View/Open
Show simple item record
Plöderl, M., & Hengartner, M. P. (2019). Guidelines for the pharmacological acute treatment of major depression : conflicts with current evidence as demonstrated with the German S3-guidelines. BMC Psychiatry, 19(265). https://doi.org/10.1186/s12888-019-2230-4
Plöderl, M. and Hengartner, M.P. (2019) ‘Guidelines for the pharmacological acute treatment of major depression : conflicts with current evidence as demonstrated with the German S3-guidelines’, BMC Psychiatry, 19(265). Available at: https://doi.org/10.1186/s12888-019-2230-4.
M. Plöderl and M. P. Hengartner, “Guidelines for the pharmacological acute treatment of major depression : conflicts with current evidence as demonstrated with the German S3-guidelines,” BMC Psychiatry, vol. 19, no. 265, 2019, doi: 10.1186/s12888-019-2230-4.
PLÖDERL, Martin und Michael Pascal HENGARTNER, 2019. Guidelines for the pharmacological acute treatment of major depression : conflicts with current evidence as demonstrated with the German S3-guidelines. BMC Psychiatry. 2019. Bd. 19, Nr. 265. DOI 10.1186/s12888-019-2230-4
Plöderl, Martin, and Michael Pascal Hengartner. 2019. “Guidelines for the Pharmacological Acute Treatment of Major Depression : Conflicts with Current Evidence as Demonstrated with the German S3-Guidelines.” BMC Psychiatry 19 (265). https://doi.org/10.1186/s12888-019-2230-4.
Plöderl, Martin, and Michael Pascal Hengartner. “Guidelines for the Pharmacological Acute Treatment of Major Depression : Conflicts with Current Evidence as Demonstrated with the German S3-Guidelines.” BMC Psychiatry, vol. 19, no. 265, 2019, https://doi.org/10.1186/s12888-019-2230-4.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.